Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
نویسندگان
چکیده
Introduction Adoptive cell therapy, where patients are treated with expanded autologous T cells derived from tumor specimens, is currently one of the most effective treatments for stage IV malignant melanoma. Clinical studies have indicated a link between treatment with anti-CTLA-4 treatment (e.g. Ipilimumab) prior to tumor removal, and a favorable treatment response to subsequent adoptive cell therapy.
منابع مشابه
تحلیل بقا در مبتلایان به ملانوم بدخیم در یزد
Background and Aim: Malignant melanoma is a rare and most malignant type of skin cancer which is originated from melanocytes. It is capable of infiltrating into interior organs and could cause mortality. The aim of this study is to analyze the survival of patients with malignant melanoma according to their age, gender, mitosis count, tumor thickness, level of lymphocyte infiltration, tumor loca...
متن کاملAdoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
PURPOSE Adoptive cell transfer (ACT) using autologous tumor-infiltrating lymphocytes (TIL) was reported to yield objective responses in about 50% of metastatic patients with melanoma. Here, we present the intent-to-treat analysis of TIL ACT and analyze parameters predictive to response as well as the impact of other immunotherapies. EXPERIMENTAL DESIGN Eighty patients with stage IV melanoma w...
متن کاملTrends in Adoptive Tumor Infiltrating Lymphocytes (TILs) Therapy
Adoptive T cell therapy based on tumor infiltrating lymphocytes (TILs) is the most effective treatment for malignant melanoma. The TILs therapy has demonstrated high overall response rates, resulting in tumor regression and prolonged survival in comparison to IL-2 and ipilimumab treatments. Expansion of TILs under exvivo conditions using patients’ own tumor tissue is a prerequisite for effectiv...
متن کاملIs there a future for adoptive cell transfer in melanoma patients?
The adoptive transfer of tumor-infiltrating lymphocytes (TILs) can yield durable responses in patients affected by metastatic melanoma. In particular, we have recently reported an 80% 3 year survival rate among patients who responded to this immunotherapeutic regimen. Of note, overall response rates were equal among ipilimumab-naïve and ipilimumab-refractory patients. Thus, the adoptive transfe...
متن کاملWhite paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Adoptive T-cell therapy (ACT) using expanded autologous tumor-infiltrating lymphocytes (TIL) and tumor antigen-specific T cell expanded from peripheral blood are complex but powerful immunotherapies directed against metastatic melanoma. A number of nonrandomized clinical trials using TIL combined with high-dose interleukin-2 (IL-2) have consistently found clinical response rates of 50% or more ...
متن کامل